-+ 0.00%
-+ 0.00%
-+ 0.00%

Shionogi completes USD 2 billion acquisition of IntraBio

PUBT·11/18/2026 00:00:41
Listen to the news
Shionogi completes USD 2 billion acquisition of IntraBio
  • Shionogi completed its USD 2 billion acquisition of all outstanding IntraBio shares, expanding its rare disease portfolio.
  • The deal, agreed on October 5, 2026, includes global intellectual property and commercialization rights for AQNEURSA (levacetylleucine).
  • AQNEURSA has U.S. and European approval for neurological manifestations of Niemann-Pick disease type C, plus U.S. approval for ataxia in Ataxia-Telangiectasia.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shionogi & Co. Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 202611171900BIZWIRE_USPR_____20261117_BW876530) on November 18, 2026, and is solely responsible for the information contained therein.